Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-12-01 Report Publication Anno…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release titled "Acticor Biotech announces its financial agenda for the 1st half of 2023." It explicitly lists future dates for key corporate events, including the '2022 Full-Year Results' and the 'Annual General Meeting' (May 12th 2023). Since the document's primary purpose is to announce the schedule of future corporate events, rather than being the report itself (like a 10-K or IR) or the announcement of a specific report's publication (RPA), it fits best as a general corporate announcement. Given the options, this type of forward-looking schedule announcement, which is not a standard regulatory filing like DIRS, DIV, or ER, falls under the general category of Regulatory Filings (RNS) as a miscellaneous corporate communication, although it is closely related to future AGM and ER events. However, since it is purely an announcement of a schedule, and not the actual AGM material (AGM-R) or the Earnings Release (ER), RNS is the most appropriate fallback for this type of forward-looking corporate calendar disclosure.
2022-12-01 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release from Acticor Biotech announcing its financial calendar for the first half of 2023. It explicitly lists the dates for the 'Résultats annuels 2022' (Annual Results) and the 'Assemblée Générale des actionnaires' (Shareholders' General Meeting). Since the document's primary purpose is to announce the schedule for future corporate events, including the AGM and the release of annual results, it functions as a general corporate announcement regarding future reporting and shareholder activity. It is not the Annual Report (10-K) itself, nor is it the Earnings Release (ER) or the AGM materials (AGM-R). It is an announcement about the timing of these events. This fits best under Report Publication Announcement (RPA) as it announces the publication schedule for other key reports, or potentially Regulatory Filings (RNS) as a general announcement. Given the specific mention of the AGM date, it relates closely to AGM/Shareholder activity, but the core content is the schedule announcement. Since it announces the date of the AGM, it is closely related to shareholder meetings, but the document itself is an announcement of the schedule, not the proxy or the results. The most fitting category for announcing the schedule of future reports and meetings is Report Publication Announcement (RPA), as it signals when the actual reports/meetings will occur.
2022-12-01 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces the start of a new clinical trial (LIBERATE study) for a drug called glenzocimab in treating myocardial infarction. It details the partnership, the study design (Phase 2b, randomized, double-blind), quotes key personnel (Professors and the CEO), and provides company background information. This format—a formal announcement of a significant business/scientific development, often released to the public and media simultaneously—is characteristic of a general press release or regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific shareholder document (DEF 14A, DVA), the most appropriate classification is the general regulatory/miscellaneous announcement category, RNS, as it serves as a public disclosure of a material event. It is not an Earnings Release (ER) because it focuses on clinical trial progress, not financial results. It is not an Investor Presentation (IP) as it is a narrative press release, not a slide deck. It is not a Legal Report (LTR) as it is announcing a trial, not reporting on existing litigation. Therefore, RNS (Regulatory Filings / General Regulatory Announcements) is the best fit.
2022-11-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "University of Birmingham News Release" and details the launch of a new clinical trial (LIBERATE) testing the drug glenzocimab for heart attacks. It includes quotes from researchers and executives, trial design details (Phase 2b, patient recruitment), and background information on the drug and the involved entities (University of Birmingham, Acticor Biotech). This content is characteristic of an announcement regarding research progress or a new initiative, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a press release announcing a significant development (a clinical trial launch), it does not fit the specific categories like AGM-R, 10-K, ER, or IR. It is a general announcement that is not covered by DIRS, DIV, or CAP. Given the options, the most appropriate classification for a general, non-mandatory regulatory press release announcing a partnership and a new clinical trial is the fallback category, Regulatory Filings (RNS), as it serves as a general public disclosure.
2022-11-22 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of October 31, 2022). It explicitly references Article 223-16 of the General Regulation of the AMF (Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of a specific date (31/10/2022). This type of mandatory periodic disclosure regarding the share capital structure and voting rights is typically classified as a regulatory filing or a specific announcement related to share capital changes, but given the options, it most closely relates to changes in share structure or mandatory regulatory reporting that isn't a full financial report (10-K, IR) or a director's dealing (DIRS). Since it details the total number of shares and voting rights, it falls under the scope of share capital information. The closest specific category is 'Share Issue/Capital Change' (SHA) or, if viewed as a general regulatory update, 'Regulatory Filings' (RNS). However, because the core content is the calculation and reporting of the total number of shares and voting rights, which directly impacts the capital structure, SHA is a strong candidate. Alternatively, if this is a standard monthly disclosure required by the exchange/regulator that doesn't fit elsewhere, RNS is the fallback. Given the specific nature of reporting total shares and voting rights, which is often a precursor or component of capital structure announcements, I will lean towards SHA, but RNS is also plausible if this is purely a compliance filing. Since the document explicitly reports the 'Nombre total d'actions composant le capital social' (Total number of shares comprising the share capital), SHA is the most precise fit among the provided options for capital structure updates, even if it's a routine monthly report rather than a major issuance.
2022-11-07 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled "Disclosure of the total number of voting rights and shares as of October 31, 2022" and explicitly references compliance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority (AMF). This type of mandatory disclosure, detailing the total share capital and voting rights on a specific date, is a standard regulatory filing in France. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific regulatory disclosure that doesn't fit the other precise categories (like DIRS, MANG, or DEF 14A), it falls best under the general regulatory announcement category, RNS, or potentially DVA if it were voting results, but here it is a share count disclosure. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a specific, mandatory, non-financial report regulatory update that isn't covered elsewhere. However, the content is very specific to share capital and voting rights, which sometimes aligns with DVA (Declaration of Voting Results & Voting Rights Announcements) or SHA (Share Issue/Capital Change). Since it is a periodic disclosure of the total number of voting rights, DVA is a strong candidate, but RNS is the safest general regulatory filing category when the specific nature isn't perfectly matched by the provided definitions, although DVA is closer to the subject matter (voting rights). Let's re-evaluate: DVA is for 'Official results from shareholder votes'. This is a disclosure of the *total number* of rights, not the *results* of a vote. Therefore, RNS (General regulatory announcements) is the best fit as it is a mandatory regulatory disclosure.
2022-11-07 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.